Haemonetics Corp. (HAE) Misses Q2 EPS Views; Affirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $118.51 +2.02%
Revenue Growth %: +5.6%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +5.6%
Financial Fact:
Net revenues: 220.25M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q2 EPS of $0.65, $0.13 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $170.6 million versus the consensus estimate of $170.4 million.
Affirms outlook.
Affirms outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- First Citizens Bancshares (FCNCA) reported Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
